

Ref. No.: NLL/CS/2025- 605

November 11, 2025

To,
National Stock Exchange of India Limited
Listing Department,
Exchange Plaza, Bandra Kurla Complex,
Bandra (E), Mumbai 400 051

BSE Limited
Corporate Relationship Department,
P J Towers, Dalal Street,
Mumbai 400 001

Symbol: NECLIFE

Scrip Code: 532649

Sub: Disclosure under Regulation 30 and other applicable provisions of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("SEBI LODR Regulations")– Completion of Slump Sale and Asset Sale

Ref: 1. Stock exchange intimation vide letter no. NLL/CS/2025- 514 dated July 07, 2025, and Annexure 1 and Annexure 2 thereof.
2. Stock exchange intimation vide letter no. NLL/CS/2025- 574 dated September 16, 2025.
3. Stock exchange intimation vide letter no. NLL/CS/2025- 591 dated October 17, 2025.

Dear Sir/ Madam,

Pursuant to Regulation 30 of the SEBI LODR Regulations and further to the aforesaid stock exchange intimations relating to the: (i) business transfer agreement ("**BTA**") executed between Nectar Lifesciences Limited ("**Company**") and Ceph Lifesciences Private Limited ("**Purchaser**") dated July 07, 2025; and (ii) asset purchase agreement executed between the Company and the Purchaser dated July 07, 2025 ("**APA**"), we wish to inform you that:

- (a) the Company has completed the slump sale of its active pharmaceutical ingredients and formulations business ("**Business**") to the Purchaser, in accordance with the terms of the BTA. The transfer is completed with effect from November 10, 2025; and
- (b) the Company has completed the asset sale to the Purchaser and completed all the completion deliverables as detailed in the APA on November 10, 2025.

Kindly take the same on record.

Thanking you,

Yours faithfully,

For **Nectar Lifesciences Limited**

(Sanjaymohan Singh Rawat)

Company Secretary & Compliance Officer